目次

Table of Contents

Executive Summary

Market Overview

Market Landscape
Market ecosystem
Value chain analysis

Market Sizing
Market definition
Market segment analysis
Market size 2020
Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
Five forces summary
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

Market Segmentation by Application
Market segments
Comparison by Application
RA - Market size and forecast 2020-2025
Psoriasis - Market size and forecast 2020-2025
MS - Market size and forecast 2020-2025
Market opportunity by Application

Market Segmentation by Drug Class
Market segments
Comparison by Drug Class
Anti-inflammatory biologicals - Market size and forecast 2020-2025
Corticosteroids - Market size and forecast 2020-2025
NSAIDs - Market size and forecast 2020-2025
Market opportunity by Drug Class

Customer Landscape

Geographic Landscape
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
Asia - Market size and forecast 2020-2025
ROW - Market size and forecast 2020-2025
Key leading countries
Market opportunity by geography
Market drivers
Market challenges
Market trends

Vendor Landscape
Vendor landscape
Vendor landscape
Landscape disruption

Vendor Analysis
Vendors covered
Market positioning of vendors
AbbVie Inc.
Amgen Inc.
AstraZeneca Plc
Bayer AG
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson and Johnson
Merck and Co. Inc.
Novartis AG
Pfizer Inc.

Appendix
Scope of the report
Currency conversion rates for US$
Research methodology
List of abbreviations

Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Key Finding 9
9: Parent market
10: Market characteristics
11: Offerings of vendors included in the market definition
12: Market segments
13: Global - Market size and forecast 2020 - 2025 ($ billion)
14: Global market: Year-over-year growth 2020 - 2025 (%)
15: Five forces analysis 2020 & 2025
16: Bargaining power of buyers
17: Bargaining power of suppliers
18: Threat of new entrants
19: Threat of substitutes
20: Threat of rivalry
21: Market condition - Five forces 2020
22: Application - Market share 2020-2025 (%)
23: Comparison by Application
24: RA - Market size and forecast 2020-2025 ($ billion)
25: RA - Year-over-year growth 2020-2025 (%)
26: Psoriasis - Market size and forecast 2020-2025 ($ billion)
27: Psoriasis - Year-over-year growth 2020-2025 (%)
28: MS - Market size and forecast 2020-2025 ($ billion)
29: MS - Year-over-year growth 2020-2025 (%)
30: Market opportunity by Application
31: Other1 - Market share 2020-2025 (%)
32: Comparison by Other1
33: Anti-inflammatory biologicals - Market size and forecast 2020-2025 ($ billion)
34: Anti-inflammatory biologicals - Year-over-year growth 2020-2025 (%)
35: Corticosteroids - Market size and forecast 2020-2025 ($ billion)
36: Corticosteroids - Year-over-year growth 2020-2025 (%)
37: NSAIDs - Market size and forecast 2020-2025 ($ billion)
38: NSAIDs - Year-over-year growth 2020-2025 (%)
39: Market opportunity by Other1
40: Customer landscape
41: Market share by geography 2020-2025 (%)
42: Geographic comparison
43: North America - Market size and forecast 2020-2025 ($ billion)
44: North America - Year-over-year growth 2020-2025 (%)
45: Europe - Market size and forecast 2020-2025 ($ billion)
46: Europe - Year-over-year growth 2020-2025 (%)
47: Asia - Market size and forecast 2020-2025 ($ billion)
48: Asia - Year-over-year growth 2020-2025 (%)
49: ROW - Market size and forecast 2020-2025 ($ billion)
50: ROW - Year-over-year growth 2020-2025 (%)
51: Key leading countries
52: Market opportunity by geography ($ billion)
53: Impact of drivers and challenges
54: Vendor landscape
55: Landscape disruption
56: Industry risks
57: Vendors covered
58: Market positioning of vendors
59: AbbVie Inc. - Overview
60: AbbVie Inc. - Product and service
61: AbbVie Inc. - Key offerings
62: AbbVie Inc. - Key customers
63: AbbVie Inc. - Segment focus
64: Amgen Inc. - Overview
65: Amgen Inc. - Business segments
66: Amgen Inc. - Key offerings
67: Amgen Inc. - Key customers
68: Amgen Inc. - Segment focus
69: AstraZeneca Plc - Overview
70: AstraZeneca Plc - Product and service
71: AstraZeneca Plc - Key offerings
72: AstraZeneca Plc - Key customers
73: AstraZeneca Plc - Segment focus
74: Bayer AG - Overview
75: Bayer AG - Business segments
76: Bayer AG - Key offerings
77: Bayer AG - Key customers
78: Bayer AG - Segment focus
79: F. Hoffmann-La Roche Ltd. - Overview
80: F. Hoffmann-La Roche Ltd. - Business segments
81: F. Hoffmann-La Roche Ltd. - Key offerings
82: F. Hoffmann-La Roche Ltd. - Key customers
83: F. Hoffmann-La Roche Ltd. - Segment focus
84: GlaxoSmithKline Plc - Overview
85: GlaxoSmithKline Plc - Business segments
86: GlaxoSmithKline Plc - Key offerings
87: GlaxoSmithKline Plc - Key customers
88: GlaxoSmithKline Plc - Segment focus
89: Johnson and Johnson - Overview
90: Johnson and Johnson - Business segments
91: Johnson and Johnson - Key offerings
92: Johnson and Johnson - Key customers
93: Johnson and Johnson - Segment focus
94: Merck and Co. Inc. - Overview
95: Merck and Co. Inc. - Business segments
96: Merck and Co. Inc. - Key offerings
97: Merck and Co. Inc. - Key customers
98: Merck and Co. Inc. - Segment focus
99: Novartis AG - Overview
100: Novartis AG - Business segments
101: Novartis AG - Key offerings
102: Novartis AG - Key customers
103: Novartis AG - Segment focus
104: Pfizer Inc. - Overview
105: Pfizer Inc. - Business segments
106: Pfizer Inc. - Key offerings
107: Pfizer Inc. - Key customers
108: Pfizer Inc. - Segment focus
109: Currency conversion rates for US$
110: Research Methodology
111: Validation techniques employed for market sizing
112: Information sources
113: List of abbreviations